This protocol addresses progressive myoclonic epilepsy in adults aged 16 years and older who present with myoclonic seizures. Therapy selection must account for the specific seizure type and individual patient factors.
Evidence-based guidance supports initiating monotherapy with a single indicated antiepileptic drug, individualised to the patient. The choice of agent depends on the seizure type. The complete regimen — including which agents are recommended at which evidence levels, and how therapy is titrated — is set out in the full protocol.
Freedom from seizures. The structured protocol also addresses long-term management once sustained seizure freedom is achieved.